In this review of the recent literature, the contribution that the new techniques of molecular genetics has made in the analysis and diagnosis of human ophthalmic conditions is presented and discussed. Among the disorders reviewed are X-linked retinitis pigmentosa, Norrie's disease, gyrate atrophy and retinoblastoma, and there are also sections on crystallins and visual pigments.
The advent of recombinant DNA technology has resulted in dramatic advances both in the analysis and in the diagnosis of human inher ited diseasel-3 as well as increasing our under standing of the underlying molecular defect. Many major disorders affecting the eye have a genetic basis, and a high proportion appear to show X-linked inheritance (Fig. 1 ). There are also many other inherited conditions, which while primarily affecting other tissues, also have ophthalmic consequences. It is not very surprising, therefore, to find that the new techniques have already been used in the analysis and diagnosis of a range of ophthalmic conditions. The contribution that molecular genetics has made in this area is presented and discussed; its progress to date is charted and its future potential in research into eye disease assessed. A broad approach has been adopted, placing the greatest emphasis upon those studies judged to have made the most significant contributions to this topic.
Recombinant DNA technology is both methodologically uniform and remarkably versatile. The discovery of restriction enzymes, the site specific endonucleases that allow us to cleave large DNA fragments at defined sites, together with the development of techniques to 'mass-produce' these fragments (DNA cloning), have together her alded a breakthrough in our approach to solving many biological problems.
The size of the human genome, 3 x 109 base pairs (bp), has for a long time been a consider able barrier to its detailed analysis. Our new found ability to dissect the genome has greatly increased our knowledge of its structure and function both at a gross level and at the level of the gene. 4 The genome contains many repetitive sequences, some of which are func tional (e.g. ribosomal RNA genes), some of which are probably not. In addition there is also a substantial single copy component: DNA sequences which occur only once in the genome. A part of this, estimated to be about 5 per cent of the total DNA complement, comprises the coding portion of the genome, containing about 150,000 different gene sequences. Thus, even the smallest human chromosome, 21, may well contain as many as 2,000 genes in its approximately 50 million bp.
Each individual gene differs not only with respect to its DNA sequence specifying the amino acid sequence of the protein product it encodes, but also with respect to its structure. Mapping of specific genes or DNA regions has been made possible by the discovery of restriction enzymes. When total genomic DNA, made from an ea,sily accessible tissue such as blood, is transferred from the agarose gel upon which it is size-fractionated, to a nitrocellulose membrane, it can be challenged with a radiolabelled probe (gene or DNA seg ment) to reveal the structure of the homolo gous region of DNA in the genome. This technique, known as 'Southern blotting', 5 has now permitted the detection and analysis of many different pathological changes at the level of the gene. Thus it is now known that most genes in higher organisms are not contiguous as orig inally thought, but are a complex mosaic of coding (exons) and non -coding (introns) sequences which must be processed to pro duce a mature RNA transcript. This process ing involves the removal of introns in the original transcript followed by the splicing together of the exons. It is therefore evident that a considerable number of different levels exist at which regulation may occur, and hence an equal number of different levels at which an aberration within the gene may exert its pathological effects. Not surprisingly, the diversity of the mutations found to underlie genetic diseases has reflected the complexity of both the structure and regulation of human genes. 6 Point mutations, insertions, deletions and rearrangements may all cause genetic disease by altering or even abolishing the activity of the gene product. Each may occur within a coding region, within an intron, in a mes senger RNA (mRNA) splice junction, or each may alter or encompass specific sequences which perform a structural or regulatory func tion. Indeed, each may interrupt, alter, or otherwise interfere with any stage in the path way of expression from gene to protein product.
Direct detection of the mutation underlying the disease state has now been accomplished in over 40 single-gene defects. 1.2 For diagnos purposes, direct analysis is the most reliable, informative and hence most desirable means of detection. The absolute requirement for direct analysis is the possession of the appro priate gene (or oligonucleotide) probe. Dele tions of a gene, or within a gene sequence, can be readily detected since the size of restriction fragments derived from that gene and detected by Southern blotting will be altered or even completely removed. A very small deletion may, however, remain undetectable if it does not result in the removal of a restric tion site since electrophoretic resolution is limited. Point mutations that introduce or remove a restriction site will also alter the size of restriction fragments generated by a given enzyme. Where the point mutation has occurred outside a restriction site, the precise position and nature of the change may be determined by DNA sequencing. Ultimately, the mutant allele may be conveniently dis tinguished from its 'wild-type' counterpart by virtue of its differential hybridisation under specific conditions to a synthetic oligo nucleotide complementary to a short region of DNA around the site of the mutation. 7 If the gene deficit is not a gross deletion, then it may often go undetected due to the lack of a suitable restriction enzyme. In this case, restriction fragment length polymor phisms (RFLPs) around the gene may be used as chromosome markers in order to track the disease allele through a family pedigree. RFLPs are neutral changes in DNA sequence which are found frequently within normal populations. 8 The vast majority of RFLPs are single base-pair changes that introduce or remove a restriction site, thus changing the mobility of DNA fragments as separated by gel electrophoresis. 8 RFLPs identified by vari ous X chromosome-specific probes and their map position are shown in Pig. 2. Although RFLPs will eventually permit the construction of a genetic linkage map of the entire human genome,9 their importance in this context lies in their utility in permitting discrimination between the two chromosomes of each homologous pair. This provides the means to 'tag' the chromosome containing the disease allele and track it through multi generational pedigrees. This approach can also be employed to track disease alleles in cases where the disease gene has not been cloned and may not be known. Instead of a cloned gene, a poly morphic DNA segment from the same region of the chromosome is used as a marker. The first step is to establish linkage between the cloned polymorphic DNA segment (the 'marker' locus) and the disease locus. If link age is tight, and therefore recombination events unlikely, this form of indirect analysis may be successfully employed to track the disease allele through multigenerational ped igrees. The possibility of error arises, how ever, due to the potential for a recombination event occurring between the marker and the disease locus. This error, and therefore the genetic distance between marker an d di sease loci, should be established before 'gene track ing' is applied diagnostically.
The tighter the linkage between the marker locus and the locus of interest, the smaller will be the number of recombinants as both loci tend to segregate together. Linkage analysis is then performed by applying likelihood methods to the common segregation of two or more 10ci.1O Briefly, a value of 8, the recom bination fraction, is derived such that the like-!ihoo� o( obtaining the observed phenotype s IS maXimised. C omparison of the likelihood of linkage at a given value of 8 with the likeli hood of obtaining the observed phenotypes when the loci are unlinked (8 = 0. 5) permits either confirmation or exclusion of linkage on a statistical basis (the 'lod score'). By con vention, a lod score of + 3.00 is taken as evi- dence for linkage, while a lod score of -2.00 is regarded as proof of independent segregation.
In molecular genetics, disease analysis and nosis are inextricably linked. Both may be possible if the appropriate cloned gene probe is available. If it is not, the establishment of close linkage will provide the basis of a diag nostic test long before the gene itself is iso lated. A molecular biological explanation of an inherited disease state requires the prior localisation and isolation of the disease gene and the elucidation of its structure both at a gross level and at the level of the DNA sequence. Approaches and strategies towards these goals in the sphere of research into eye disease will be presented and discussed.
Retinitis Pigmentosa (X-Linked)
Retinitis pigmentosa is a group of disorders characterised by night blindness, constriction of the visual fields and characteristic changes in the fundi. There is genetic heterogeneity and, in the United Kingdom, the autosomal dominant form and the X-linked form com prise 24 per cent and 22 per cent respectively of the total cases observed. II Linkage analysis has been applied so far only to the X-linked form. Molecular biological techniques are most easily applied to X-linked disorders, firstly because a sex-linked pattern of inheri tance obviates the need for a genome-wide search for the defective gene and secondly because the X chromosome is already satur ated with cloned and regionally-localised polymorphic DNA segments which may be employed as linkage markers. The X-linked retinitis pigmentosa gene was first localised by Bhattacharya et a/.12 by estab lishing linkage to an anonymous DNA seg ment L1.28 (DXS7). This sequence is a 1.25 kilobase (kb) single-copy genomic EcoRI fragment which has been assigned to the short arm of the X chromosome (Xp11.O-p11.3)13 and which detects polymorphic alleles (9 kb or 12 kb) with the restriction enzyme, Taq!. These authors, in their analysis of five fam ilies, found a maximum lod score of 7.89 at a recombination fraction, 8, of 0.03. While this then is the most likely distance between the marker and X-linked retinitis pigmentosa locus, 95 per cent confidence limits for the location of the retinitis pigmentosa gene were given as 0-15 centimorgans (cM) from the DXS7 locus.
Further studies have now been carried out The gene order of these loci on the X -chro mosome was determined by applying three point linkage analysis to a large Danish ped igree using both the Ll.28 probe and a C -ban ding heteromorphism (Xcen), thought to be a flanking marker.17 Genetic distances were estimated by pairwise lod score analysis and the map order given below is the most likely of the several alternatives:
Francke et al.18 described a male patient with a small interstitial deletion of Xp21 who suf fered from Duchenne muscular dystrophy, chronic granulomatous disease, McLeod syn drome and retinitis pigmentosa. The presence of a deletion was confirmed in this patient by the absence of hybridisation of his DNA to probe 754 (DXS84). However, the localisa tion of the X -linked retinitis pigmentosa gene implied by this close association with Duch enne muscular dystrophy is inconsistent with linkage data from the above DXS7 studies. It was thus thought that either the cytological and genetic maps of this region were very different or that genetic heterogeneity existed in X -linked retinitis pigmentosa. Clayton et al. 19 have argued against heterogeneity and suggest instead an error in diagnosis; indeed the clinical description of retinal dystrophy manifested by the patient of Francke et al. 18 was unlike that normally encountered in X-linked retinitis pigmentosa.
Buetow et al.20 tested for genetic hetero geneity in X-linked retinitis pigmentosa, but the results were equivocal. Moreover, the method used to detect heterogeneity divided the sample on the basis of presence or absence of the tapetal reflex in female carriers. The occurrence of intra-familial variation for this phenotypic difference suggests that this divi sion is artificial. Clayton et al. 19 found no evi dence of genetic heterogeneity in 13 families and combining data from all studies to date, reported a lod max of 14.01 at e = 0.08. For the purposes of gene mapping at least, genetic heterogeneity need not be postulated for X -linked retinitis pigmentosa.
For clinical purposes, however, Clayton et al. 19 have argued that the question of het erogeneity must still be considered and a conservative estimate of risk should be calcu lated. These authors concluded that for fam ilies in which no recombination between Ll.28 and X -linked retinitis pigmentosa has been observed, the mean risk is about 10 per cent for misdiagnosis. The mean risk is a more accurate measure of the risk to the individual being screened since it takes into account risk at values of 8 other than at lod max. It follows that L1.28 should be useful for carrier detec tion and early diagnosis of X -linked retinitis pigmentosa in the 40 per cent of cases in which the families are informative for variation at the DXS7 locus.
The proportion of families for which diag nosis is possible will be increased by the detec tion of additional high -frequency poly morphic variation at the DXS710cus but only if no significant linkage disequilibrium (non random association) with the known TaqI RFLP is present. Flanking markers and mark ers closer to the retinitis pigmentosa gene itself are also urgently needed to improve the reliability of diagnosis. This is because use of these markers will not only increase the prob ability of any one family being informative, but will also reduce the risk of misdiagnosis since errors in pedigree analysis would then be due solely to the occurrence of double crossovers. It should be stressed, however, that in addition to the possible existence of genetic heterogeneity, other sources of error will include the clinical diagnosis itself and non-paternity. 17 
Choroideremia
Choroideremia is another X-linked disorder in which males suffer progressive visual loss from childhood, resulting from profound atrophy of the choroid. Heterozygous females show little or no visual defect but usually exhibit a characteristic fundus appearance with spotty pigmentation in the midperiphery of the retina with focal areas of pigment epi thelial atrophy. Molecular biological studies of this condition have adopted two approaches:
(1) linkage studies using polymorphic DNA segments as markers to track the disease, and (2) the mapping and delineation of X chro mosome deletions associated with the disease.
In practice, these approaches are often not mutually exclusive. Nussbaum et al.21 studied three families and· established linkage between the choroideremia locus and the polymorphic marker segment, DXYS1, localised to Xq13-q21. No recombinations were found between marker and disease locus and a lod max value of 5.78 was calculated at a recombination frac tion, 9, of 0.00 (90 per cent confidence limits, 0<9<0.09). This finding has since been con firmed by Jay et al.22 (lod max = 4.95 at 9 = 0.00) and Sankilaetal.23 (lod max = 11.44 at 9 = 0.00).
Linkage was also found between choroideremia and the DNA segment DXS1121,24 located at Xq24-q26 (lod max = 1.54 at 9 = 0.00; 90 per cent con fidence limits, 0.00<9<0.30). This finding together with the absence of measurable link age of choroideremia to the HPRT locus21 at Xq26-q27 suggested that the choroideremia locus may lie between DXYS1 and DXSll in the region Xq13-q24. This postulate is now supported by the study of Jay etal.22 which analysed segregation data from 15 choroideremia families. These authors also reported segregation data for DXS14, DXS178 and DXS177 compatible with very loose linkage to the choroideremia locus. Close linkage between the DXYS12 locus (Xq13-q22) and choroideremia has been reported (lod max = 3.31 at 9 = 0.00)23 but the linkage relationship to other markers is not yet known. In the absence of recombina tion between the disease and marker loci, no precise localisation of the disease locus can be obtained since genetic distance is a function of recombination frequency. However, Gal et al.25 using markers DXYS1 (Xq13-q21), DXS3 (Xq21.3-q22) and DXSll (Xq24-q26) in two informative families, have reported recombinants and have suggested the map order shown below:
When the data of Gal et al.25 are combined with those of Nussbaum et al.2l the estimated genetic distances between markers DXYS1 and DXSl1 and choroideremia are 8 cM and 10 cM respectively,25 i.e. 9 at lod max = 0.08 and 0.01 respectively. The reported close link age of DXS3 to choroideremia (lod max = 7.7 at 9 = 0.03:26 lod max = 12.32 at 9 = 0.04)27 supports the validity of this map order.
The most detailed study to date is that of Lesko et al.28 which utilised 9 polymorphic DNA segments between Xp11.3 and Xq2.6 to derive a 'multipoint linkage map' of this region of the X chromosome. Multipoint link age analysis provides the means to assess the linkage relationship of more than two markers simultaneously and is an extremely powerful tool in establishing gene order on the chromo some. In the study of Lesko et al. ,286 RFLP markers from the region Xq13-Xq22 were found to reside between 0 and 4 cM away from the choroideremia locus. Multipoint linkage analysis suggested the most likely order to be:
Xcen --DXS1 --choroideremia --DXS17 --qter in agreement with the data of Gal et al. 25 While maps of this kind should eventually permit clinical diagnosis, this is probably pre mature at this stage. This is because in the absence of recombination between some of the above markers and the choroideremia locus reported in three sizeable studies21-23 the question of genetic heterogeneity must, at least for the time being, remain open.
Studies such as those outlined above should permit a n tenatal diagnosis in families at risk of choroideremia using informative markers such as DXYS1. lithe map order given above is confirmed and flanking markers can indeed be employed in linkage studies, then the reliability of diagnosis will be greatly enhanced. Although choroideremia is usually fairly rare, its prevalence in some populations may be very high, e.g. in Northern Finland.23 In this population, the disease occurs mainly in three large kindreds; the founder having been traced back 12 generations.23 It is poss ible that haplotype analysis of RFLPs associ ated with the linked DNA segment, DXYSl, will prove very useful for diagnosis in these kindreds.
A cytologically -detectable deletion associ ated with choroideremia encompassing the region Xq21 was described by Rosenberg et al. 29 Using DNA segments from the region as hybridisation probes, these authors demon strated that the DXYSI locus, but not the DXS17 locus (Xq21.3-q22), was deleted. This further narrowed down the location of the choroideremia locus to Xq21.2-q21.33. In a more complete study of a family in which choroideremia was segregating with a dele tion of sub-band Xq21.1, Hodgson et alY demonstrated that DNA sequences homolo gous to both DNA segments DXYSI and DXS3 were absent in an affected male but present in a single dose in his mother and sister. Chorionic villus sampling and hybridisation of DXYSI and DXS3 to fetal DNA permitted prenatal exclusion of choroideremia in the sister's unborn male fetus.
Norrie's Disease
This X-linked disorder presents with pseudotumours of the retina, retinal hyper plasia and necrosis of the inner layer of the retina, and cataract. Mental retardation is also fairly frequent.
Linkage studies to date have succeeded in establishing linkage between Norrie's disease and the locus DXS7 as defined by the TaqI RFLP detected with anonymous DNA seg ment L1.283 0 ,31 which has been localised to Xpl1.3. No recombination has been found between DXS7 and the locus of Norrie's disease (lod max = 3.81 at e = 0.00). In addi tion, possible linkage was detected between the C -banding heteromorphism, Xcen, and Norrie's disease (lod max = 1.99 at e = 0.09). Data for DXS16 (Xp22) were also compatible with loose linkage. The potential for antenatal diagnosis is good, but since no recombination events were detected between DXS7 and Nor rie's disease, no estimate of genetic distance could be derived.
Two different deletions have so far been analysed using recombinant DNA methodol ogy. Neither deletion was detectable cytologically and their existence was only demonstrated by the absence of hybridisation to the DXS7 probe.32,33 Obligate hetero zygotes showed hybridisation band intensities consistent with hemizygosity at the DXS7 locus. In addition to DXS7, 9 cloned DNA sequences from the Xpll-p21 region were recruited in an unsuccessful attempt to deline ate the boundaries of the deletion.33 Dele tions, however, may not be a common cause of Norrie's disease since deletion of DXS7 was not found in a further 11 cases studied by Gal et al.33 It nevertheless remains possible that small deletions are frequent but do not neces sarily encompass the DXS7 locus. In one of the above deletion studies,32 the prenatal exclusion of Norrie's disease in a male fetus of a carrier mother was demonstrated. Hybridisation of DXS7 to DNA derived from a chorionic villus sample from a male fetus confirmed that the fetus was unaffected.
Hereditary Cataract and the Crystallin Gene Family
Cataract is a generic term to describe a variety of conditions, both inherited and acquired, where the normally clear lens has become opaque. Cataract is also common in a variety of inherited conditions including Lowe's oculocerebrorenal syndrome, Norrie's disease, Usher's syndrome, retinitis pigmen tosa, and Fabry's disease.34 Those cataracts recognised as being inherited have been known for many years to be heterogeneous and this was confirmed by conventional link age studies.35-37 Linkage studies in affected families using RFLPs should identify the loci responsible and help unravel the hetero geneity seen clinically.
One approach to localise cataract loci would be a genome -wide search using arbitr ary polymorphic DNA segments as markers to search for linkage with a given form of hereditary cataract. Since this is clearly very laborious, it is only sensible to test first (and if necessary exclude) all 'good' candidate genes before embarking upon such a search. One such candidate for involvement in hereditary cataract is the crystallin gene family. Since the crystallins have been very well reviewed elsewhere,38-4 0 only a cursory description of the human genes will be given here.
The crystallins are a family of highly con served lenticular proteins which, in humans, may be divided into three classes: alpha, beta, and gamma. The two alpha genes (alpha-A2 and alpha-B2) have been localised to chromo some 21 and 16 respectively, 41 two of the beta genes (beta-A3/A1 and beta-B2) have been localised to chromosomes 1742 and 22 (M. Gorin, personal communication) respec tively, while the gamma genes are clustered on the long arm of chromosome 2.43. 44 The gamma crystallins are the best characterised of the human crystallins. A total of seven have been detected; five encode highly homolo gous gamma crystallin proteins, two are non functional pseudogenes.45-47 Sequence com parison of the functional gamma crystallin genes have identified sequences 5' to the genes which could be involved in the regu lation of lens-specific gene expressionY Lubsen et al. 48 adopted the candidate gene approach for Coppock cataract using a cloned gamma crystallin gene as a probe. Not only were they able to establish linkage (lod max = 7.58 at e = 0.00) but they were also able to demonstrate that an RFLP haplotype (specific combination of RFLP alleles at adja cent sites on the same short stretch of chromo some) was specific to family members who suffered from cataract. This analysis does not prove that the aberrant gene causing Coppock cataract and the gamma-crystallin gene are one and the same. However, the two are necessarily very closely linked and this analy sis does provide strong evidence for their identity. If this were not so and the two loci were located at a considerable distance from each other, the observed RFLP-haplotype associations would rapidly disappear within a few generations. 49 Further evidence for the involvement of the crystallins in hereditary cataract has come from mouse studies. For example, cataracts in the Philly and Fraser mice have been attributed to a loss of beta and gamma crys tallin mRNAs respectively.5 0 .51 Moreover, a gamma-crystallin gene has been used as a probe to demonstrate the occurrence of a 50 per cent reduction in gamma-crystallin mRNA in the murine dominant cataract NOP (nuclear opacity) mutant. 52 The testing of the remaining members of the crystallin multigene family in human ped igrees where other forms of hereditary catar act are segregating, is eagerly awaited. One good candidate appears to be the chromo some 21-encoded alpha-crystallin gene; catar act is commonly found in individuals with Down's syndrome (trisomy 21). Another possible candidate gene for hereditary catar act is the major intrinsic protein gene, now localised to chromosome 12.53
Gyrate Atrophy
Gyrate atrophy is an autosomal recessive receptor dystrophy resulting in a progressive loss of vision due to sharply demarcated circu lar areas of chorioretinal atrophy. Patients with gyrate lltrophy exhibit hyperor nithinaemia and a deficiency of the mitochondrial enzyme, ornithine ketoacid aminotransferase. This enzyme catalyses the interconversion of ornithine and alpha ket oglutamate to pyrroline-5' carboxylate and glutamate.
Two groupS54 . 55 have isolated cDNA (copy DNA, made by reverse transcriptase from an expressed mRNA template) clones for ornithine aminotransferase. Using these clones as probes, the chromosomal genes have now been studied. The ornithine aminotransferase gene is a member of a gene family consisting of at least four copies on different chromosomes. 56 Two loci have been found to be located on lOq26 and Xp11.2 by in situ hybridisation studiesY The former is thought to be a functional gene and is a candi date for involvement in gyrate atrophy on account of its autosomal location.
The ornithine aminotransferase cDNA contains a 1,317 bp coding region, plus 44 bp of 5' and 654 bp of 3' untranslated sequences. 54 It hybridises to a 2.2 kb poly A + mRNA species in liver, fibroblasts and lym phoblasts. Ramesh et al.54 studied seven patients with gyrate atrophy but failed to find any evidence for deletion or rearrangement of the ornithine aminotransferase genes using a total of 11 restriction enzymes. The absence of detectable mutation in the gene has also been reported by Inana et aI.56 in their study of 24 patients with gyrate atrophy. Ramesh et al. 54 also found the size and approximate amount of ornithine aminotransferase mRNA to be unaltered in the fibroblasts or lymphoblasts of their patients despite a concomitant 25-100 fold reduction in ornithine aminotransferase enzyme activity. However, Inana et al. 56 reported one example of a shortened ornithine aminotransferase mRNA and one of total absence of the mRNA in two of their patients with gyrate atrophy. Deletions there fore appear to be rare and the study of muta tions at the ornithine aminotransferase locus will require the isolation and sequencing of mutant genes from patients with gyrate atrophy.
Linkage Analysis and Other Eye Disorders
Although most of the linkage studies carried out to date have involved one of the X-linked diseases, retinitis pigmentosa, choroideremia or Norrie's disease, progress is also being made in other ophthalmic conditions.
One of these is X-linked retinoschisis, characterised by foveal retinoschisis in all cases and true retinoschisis (intraretinal split ting) in about half. Wieacker et al.58 found some evidence for loose linkage between Re8 (DXS9), localised to Xp22, and X-linked reti noschisis (lod max = 1.74 at 8 = 0.15).
Further analysis59 with linked probes from the short arm of the X-chromosome has also demonstrated loose linkage with DXS85 (Xp22.3-p22.2; lod max = 0.91 at 8 = 0.21) and with DXS16 (Xp22; lod max = 2.14 at 8 = 0.11). If these latter markers flank the locus for X-linked retinoschisis as proposed59 then, in combination, they may prove useful in diagnosis.
The Lowe oculocerebrorenal syndrome is a rare X-linked disorder characterised by con genital cataract, mental retardation and defective renal reabsorption. Since prenatal diagnosis has not, up to the present time, been possible and carrier testing uncertain, there was an urgent need to develop the means of tracking the syndrome with RFLPs. This has The Lowe syndrome locus itself is likely to be within the region Xq24-q26.
X -linked ocular albinism has previously been shown to be linked to the Xg blood group on the short arm of the X chromo some.61,62 More precise mapping of the ocular albinism locus should soon be possible as the first linkage data from anonymous DNA seg ment studies become available, DXS85 (Xp22.3-p22,2) has already been shown to be closely linked to the ocular albinism locus (lod max = 4,60 at e = 0,00), 63 Linkage studies now appear to be under way for incontinentia pigmenti,64,65 a rare X-linked dominant condition localised to Xp11,66 and the Usher syndrome67 thought possibly to reside on chromosome 1, Since the cloning of other genes of ophthalmic signifi cance is now proceeding apace (e.g, G-pro teins, retinol-binding protein, transducin etc), we may expect future studies of eye disease to utilise these as candidate gene loci.
Molecular Genetics of Vision
Rhodopsin, a light-absorbing pigment found in the retinal rods, is a member of the opsin gene family which also includes the visual pig ment proteins found in the cones. Rhodopsin consists of an apoprotein, opsin, covalently bound to 11-cis retinal and is located in the disc membranes of the photoreceptor outer segment. The excitation of rhodopsin by light initiates the visual excitation process.
In 1983, Nathans and Hogness isolated both cDNA and genomic clones coding for bovine rhodopsin using a synthetic oligonucleotide (constructed by reference to the known amino acid sequence of the protein) as a probe. The bovine gene consists of a 96 bp 5' un translated region, a 1,044 bp coding region and a 1,400 bp 3' un translated region. It is split into five exons by a total of 3.8 kb of intervening sequence and detects a 2.6 kb mRNA when used as a hybridisation probe in Northern blotting experiments.
The bovine gene was then used as a probe to isolate genomic clones for the human rhodop sin gene. 68 The human gene is also split into five exons at exactly analogous positions and is 93.4 per cent homologous to bovine rhodop sin at the amino acid sequence level. The high est degree of homology is reserved for those residues that are potential phosphorylation or glycosylation sites or are involved in the bind ing of ll-cis retinal. For both bovine and human genes, 3 or 4 introns are immediately distal to the codons for putative trans membrane segments and one of these marks the boundary between the C-terminal and transmembrane domains. The correspon dence between structure and function has important implications for theories of gene evolution.
Colour vision is made possible by the exis tence of three light-sensitive pigments, red, green and blue, which are located in the photoreceptor membranes of the cones. The visual pigments consist of an opsin moiety covalently linked to ll-cis-retinal and absorb light maximally at different wavelengths. This absorption is the step that triggers an enzyme cascade which ultimately ends in the produc tion and transmission of a neural signal. Colour blindness, while not of great clinical significance, is remarkably common; some 8 per cent of Caucasian males exhibit red-green colour-blindness. The study of this anomaly nevertheless promises to unravel not only some of the complexities of the visual process but also to provide some insight into the mechanisms by which such variation is generated.
The genes for the human visual pigment proteins have now been cloned69 by virtue of their homology with rhodopsin. A rhodopsin gene probe was used to select clones from a human genomic library at low stringency. These were then separated into three distinct classes by restriction mapping of the cloned DNA. Finally, a human retinal cDNA library was screened for homologous clones corre sponding to coding regions for the three classes of genomic sequences. Comparison of cDNA and genomic sequences permitted the mapping of the genes. One of the genes was found to be split into five exons, (cf. rhodop sin) interspersed with non-coding DNA (introns). This gene was identified as the blue pigment gene on account of its autosomal location (chromosome 7q22-->7qter). It has been sequenced and is 42 per cent homolo gous to rhodopsin at the amino acid sequence level.
Members of the other two classes of clones were mapped to the long arm of the X chro mosome. The X-chromosomal location, iden tical to that of the genes for red-green colour blindness, argued strongly that these genes were indeed those coding for the red and green visual pigments. Red and green pig ment cDNAs were both found to consist of 6 exons, all but the first being homologous to rhodopsin.69 They were found to be 96 per cent homologous at the amino acid sequence level and were distinguished firstly by restric tion enzyme mapping and secondly by the comparison of genotype with phenotype. Males with normal colour vision have been shown to have one red and a variable number of green pigment genes, residing in a head to-tail tandem array within the X chromosome. 69 To correlate phenotype with genotype, Nathans etal. 70 restriction mapped the red and and green pigment genes from males with dif ferent forms of colour vision abnormality and compared results with those derived from 'colour-normal' controls. G-R + dichromacy (green sensitivity absent) correlated with the absence of one or more of the four EcoRI fragments homologous to the green pigment gene probe. Similarly, the G + R -phenotype (red sensitivity absent) tended to be associ ated with the loss of one or more of the red pigment-associated EcoRI fragments. Initial studies of red-green colour-blindness were then extended to encompass anomalous tri chromacy. Restriction enzyme mapping of the red and green pigment genes, together with gene quantitation analysis, indicated that these anomalies are caused not only by the absence or duplication of visual pigment gene loci but also in some instances by gene fusion resulting in the production of a hybrid pro tein. Such aberrations probably occur by unequal crossing -over or gene conversion and their high frequency is thought to be indica tive of very close linkage of the red and green pigment genes on the X chromosome. Similar observations have been made on other genes which are both highly related and adjacent on the chromosome. Interestingly, the variation in gene copy number for the green pigment genes in 'colour -normal' males is not associ ated with any phenotypic difference.
Blue cone monochromatism, an uncom mon X-linked disorder characterised by impaired visual acuity, poor colour discrimi nation, nystagmus and myopia, has recently been found to be linked to two marker loci, DXS15 and DXS52, both of which map to the vicinity of Xq28.71 Maximum likelihood esti mates of the recombination fractions are 0.05 at a lod scOre of 3.58 (DXS15) and 0.07 at a lod score of 2.39 (DXS52). Psychophysical and electrophysiological tests demonstrate normal rod and blue cone function, with absence of red and green cone function. One possible explanation for these findings is that the structure of the red and green pigment genes has been altered beyond function or deIeted. 71 Comparison of the visual pigment genes at the amino acid sequence level has suggested that three genes, including those coding for rhodopsin and the blue pigment, were derived from a common ancestor gene, the third being duplicated perhaps around 30-40 million years ago to create the red and green pigment genes.69 Future study of the opsin gene family should therefore allow us not only to under stand better the intricate molecular basis of vision, but also provide us with valuable insight into the mechanisms of gene mutation and evolution.
Retinoblastoma
Retinoblastoma is a malignant tumour of the retina occurring in infancy. It may be uni lateral or bilateral, and some cases have a positive family history for the tumour. The genetics of retinoblastoma have been studied by Vogel,n and non-hereditary reti noblastoma includes 85 per cent of unilateral cases in whom the tumour is unifocal. Heredi tary retinoblastoma, which is transmitted as an autosomal dominant trait, includes all bilateral cases, all unilateral cases with multi focal tumours, and unilateral cases with a positive family history.
Deletion carriers with retinoblastoma often have other systemic abnormalities such as mental retardation. The deletions can usually be detected cytogenetically, and deletion mapping has shown that the region involved is band 13q14.73-76 Both hereditary and non hereditary retinoblastoma are considered to arise as a result of two mutations. Knudson77 proposed the 'two-hit' hypothesis whereby hereditary retinoblastoma arises from a ger minal mutation followed by a somatic muta tion, and non-hereditary retinoblastoma arises from two successive somatic mutations affecting both homologous chromosomes in the same target cell, the embryonic reti noblast. Thus, in hereditary retinoblastoma, the first mutation is thought to predispose to tumour formation. The first mutation may be a deletion, a point mutation, an insertion or a rearrangement; it alters or abolishes the activity of one of the retinoblastoma suscep tibility loci on 13q14.
The second mutation affects the same locus on the homologous chromosome resulting in a 'loss of heterozygosity'. The second mutation may arise through chromosome loss, loss fol lowed by reduplication, mitotic recombina tion, gene conversion, translocation, deletion, insertion or possibly point muta tion.78,79 Whichever mutation occurs, the result is the same, the loss of both normal retinoblastoma alleles and hemi-or homo zygosity for the mutant allele. It is this change which is responsible for the retinoblastoma phenotype.
Deletions of the chromosomal region 13q 14 have been found in the tumours of reti noblastoma patients with normal constitu tional karyotypes,80 suggesting a post -zygotic event. Deletion mosaicism, where some cell lines have a deletion and other cell lines are normal, has been found in the tumours of some patients with retinoblastoma.81,82
Since only 5 per cent of patients with reti noblastoma have a detectable chromosome deletion,n the use of esterase D, an enzyme whose activity may be measured in all human tissues, has .proved very useful in detecting deletions which had previously gone undetected. Esterase D was first mapped to chromosome 13 by van Heyningen and col leagues,83 then more precisely to 13q14 by deletion mapping84 and genetic linkage studies.85.86.87 It has two isoenzymes; indivi duals may be homozygous for either E1 or E2, or heterozygous E1-E2. One interesting observation88 was that in 6 patients, normal constitutional cells possessed both alleles, but in four patients, the tumour cells expressed only one allele. This may have been due to various mechanisms, including a deletion of the esterase D locus, or perhaps somatic inac tivation of genes near the esterase D and reti noblastoma loci.
The activity of esterase D is, as might be expected, proportional to the number of copies of the region 13q 1489 and is 50 per cent of normal if this region is deleted. Deletions of the esterase D locus occurred in about 5 per cent of 200 retinoblastoma cases reported by Cowell et al. 90 There have been reports91.92 of normal esterase D levels in a patient with sporadic retinoblastoma and a deletion, sug gesting that the breakpoints were situated between the two loci and that the esterase D locus is proximal to that of retinoblastoma.
Electrophoretic variants of esterase D may be used for antenatal diagnosis or for postna tal screening in the few families which appear to be informative. 93 In these families, affected individuals are heterozygous for the esterase D polymorphism, their partners being homo zygotes. However, the frequency of the rare allele (E2) is low in the UK (0.116) and this limits the use of this test for antenatal diagnosis. 94 RFLPs associated with DNA segments from the long arm of chromosome 13 have been used as markers to determine the extent of loss of heterozygosity at loci on this chro mosome in tumour DNA.78.95 The specific mechanism of somatic mutation involved in the generation of hemi-or homozygosity in a given tumour can then be inferred from the extent and pattern of loss of heterozygosity observed when compared with that exhibited by constitutional chromosomes 13 from other tissues from the same individual. 78.79.96.97 Thus in one case, RFLP patterns were consistent with the non-disjunctional loss of one chro mosome 13 followed by the duplication of the remaining homologue, resulting in homo zygosity for the mutant allele. 78 The existence of a genetic map of chromosome 1398 is prov ing extremely useful in determining both the nature and the extent of the various chro mosomal changes seen in retinoblastoma.
Loss of heterozygosity at chromosome 13 loci has also been implicated in osteosar coma,99.100 a finding which suggests that the same locus may be involved in the genesis of different tumours in different tissues. Indeed the survivors of the hereditary form of reti noblastoma have a much higher likelihood of developing osteosarcoma than the general population,IOO.1 0 1 although the bone tumour may arise in some individuals in the absence of retinoblastoma.99 Similarly, loss of hetero zygosity at chromosome 13 loci has also been observed in ductal breast tumours, 1 0 2 where loss of one of the homologous chromosomes was thought to have occurred by mitotic non disjunction. Some 5 per cent of cases of ductal breast carcinoma are thought to be inherited but it is not yet known whether the reti noblastoma/osteosarcoma locus is directly involved.
A large number of DNA clones have been isolated from chromosome 131 0 3 and some have been used to map deletions in excess of 25 kb found in retinoblastoma patients.1 0 4.1 0 5 Three groupSl06-1 0 8 have now independe · ntly identified a putative candidate gene for reti noblastoma. The search strategies adopted were broadly similar; the cloning of genomic DNA sequence from the 13q14 region by 'chromosome walking'. Chromosome walk ing refers to the isolation of overlapping DNA clones from a genomic library which can then in turn be used to isolate clones still further away from the original DNA probe. This pro cess is then �llowed by the isolation of single copy DNA elements from the cloned region. Disease candidacy is then tested for on the basis that the retinoblastoma gene should be expressed in retinal cells but not in tumours. Both cDNA and genomic clones have been isolated, corresponding to a sequence which fitted this description. Restriction maps are reportedly similar for all three candidate gene inoblastomas using the retinoblastoma candi date cDNA as a probe. Sixteen of these exhibited partial or total deletion of the reti noblastoma gene, a frequency which provides encouragement for the use of this probe in antenatal diagnosis. Several cases of homo zygous internal deletion were found, thus providing clear evidence for the authenticity of the retinoblastoma cDNA. In the 60 per cent of cases where no structural change was detectable, the mRNA transcript was either abnormal or absent. Finally, a homozygous internal deletion was also found in an osteosarcoma, providing good evidence that the osteosarcoma and retinoblastoma suscep tibility genes are identical. The detection of more subtle mutations (e.g. point mutations within the coding sequence or promoter regions at the retinoblastoma/osteosarcoma locus) awaits the complete sequencing of the gene from retinoblastoma patients. Formal confirmation that this cDNA is the recessive retinoblastoma gene must, how ever, await the demonstration that reversion can be induced by introduction of the wildtype retinoblastoma allele to tumour cells in culture. A model for this approach is provided by the introduction of a normal human chro mosome 11 into a Wilms' tumour cell line which is reported to have brought about sup pression of the tumour phenotype. III An ani mal model may also be created. One way to do this would be to construct a 'transgenic' mouse by introducing an antisense reti noblastoma gene into the germline. The anti sense mRNA, produced when this artificial gene is transcribed, would by definition bind tightly to the normal retinoblastoma mRNA, and in so doing, prevent its translation. In principle, this should mimic the loss or reduc tion of the retinoblastoma susceptibility gene transcript found in retinoblastoma. Such a model would be extremely useful for the bio chemical and physiological characterisation of the pathological sequelae consequent to the presence of an aberrant retinoblastoma gene.
The human esterase D gene has recently been cloned,II2,1I3 which has permitted direct analysis of the closely linked esterase D locus in retinoblastoma. Absence of esterase D activity in the retinoblastoma cells of one reti noblastoma patient has been shown to be due to the loss of one allele at the esterase D locus. 114 While it is now clear that mutation at the esterase D locus is not a necessary accom paniment to the development of reti noblastoma, it is not yet certain whether the esterase D mutation reported by Lee et al.1I4 is independent of that which caused the reti noblastoma or whether the two events are somehow causally linked. Horsthemke et a/.lIo found that 3 out of 8 deletions at the retinoblastoma locus did not encompass the esterase D locus.
Loss of heterozygosity at loci on chromo some 11 also seems to be important in the development of another embryonic tumour, Wilms' tumour.1I5-119 One in three children with sporadic (non-familial) aniridia develops Wilms' tumour. 12 0, 121 Since these conditions usually occur together in individuals with a deletion of llp13,124,125 the association is thought to be due to the proximity of the two loci on chromosome 11. Michalopoulos et al.126 delineated the deletions in a patient with aniridia-Wilms' tumour. These authors found that the catalase locus, which maps to 11p13, was usually deleted but neither the proximal lactate dehydrogenase A locus nor the distal insulin, gamma-globin, Ha-Ras-l or calcitonin loci were absent. Similarly, Van Heyningen et at. 127 reported frequent deletion of the catalase gene in Wilms' tumour-aniridia while the calcitonin and beta-globin loci were unaffected. However, Boyd et at.128 using a catalase gene probe, have excluded deletions at the catalase locus in five patients with sporadic aniridia, one of whom had a cytologically observable deletion. The cata lase gene is now thought to lie proximal to the Wilms' tumour-aniridia region. Glaser et al. 129 have also reported the deletion of the gene encoding the beta subunit of follicle-stimulat ing hormone in patients with both aniridia and Wilms' tumour.
Two groups130,131 have recently reported ele vated expression of insulin-like growth factor-II (IGF-II) in Wilms' tumour as com pared with normal adult tissues. Although the observations were exciting in the light of other growth factors being implicated in oncogenesis, the level of IGF-II expression in tumours is comparable to that seen in embryonic tissuesl3l and appears to be inde pendent of tumour progression in Wilms' tumour. 132 Recently, it has been claimed that the alleles lost from tumour tissue are all maternal in origin.133 Since, however, the sample size was only 5 individuals, it will be necessary to examine a larger sample in order to confirm this potentially intriguing finding.
As with retinoblastoma, loss of hetero zygosity on chromosome 11 is associated with more than one tumour. Embryonal tumours, hepatoblastoma and rhabdomyosarcoma, also exhibit acquired homozygosity at various loci on chromosome 11.134 While it seems clear that the Wilms' tumour and aniridia loci are probably distinct, it remains to be seen whether the genes causing the familial and sporadic forms of aniridia are the same. Map ping of the short arm of chromosome 11 by studies such as that of Porteous et at. 135 and Mannens et at. 136 should permit the localisa tion of the aniridia locus and aid the eventual isolation of the gene.
Loss of alleles on specific chromosomes has also been observed in bladder carcinoma (chromosome 11137), uveal melanoma (chro mosome 2138), small cell lung cancer (chromo some 3139.140), renal cell carcinoma (chromosome 3141), acoustic neuroma (chro mosome 22142), meningioma (chromosome 22143), and familial adenomatous polyposis (chromosome 5144). A more general loss of heterozygosity occurs in malignant melanoma, where alleles were shown to be lost from no less than eight different chromo somes.145 Tumours like retinoblastoma thus appear to arise as a result of the functional loss of both normal alleles at the tumour locus, consistent with a model which invokes a sup pressor role for normal alleles at this locus. 79 The conceptual and methodological frame work now exists within which to analyse other tumour states which may possess a similar aetiology to retinoblastoma and the Wilms' tumour-aniridia syndrome. Good candidates to fit such a model are tumours which are associated with chromosome deletions and which occur in both sporadic and familial forms. One of the most important contri butions of RFLP analysis will be to help dis tinguish the sporadic from the familial cases with its important implications for prognosis, treatment and genetic counselling.
Isolation of Disease Loci
For molecular geneticists, the ultimate goal of disease analysis should be an explanation of the disease state at the molecular level. To this end, analysis of RFLPs associated with linked DNA segments is merely the first step towards the precise localisation, eventual isolation and finally the detailed analysis of the disease locus. Other approaches which may be helpful in furthering these aims and which are directly applicable to the analysis and diagnosis of eye disease, will therefore now be briefly discussed.
Initially, it was thought that it might be possible, once linkage had been established, to 'walk' along the chromosome towards the locus of interest. Chromosome 'walking' refers to the isolation of overlapping frag ments from a genomic library which can then in turn be used to isolate additional fragments still further away from the site of the original DNA probe. This approach146 has proved suc cessful for the mapping of regions of up to 100 kb around specific gene loci. However, progress proceeds in steps of only some 25 kb in a particular direction and success depends upon the absence of repetitive elements in the vicinity. Since most linked DNA segments are a minimum of several centimorgans from a disease locus (on average this genetic distance corresponds to several thousand kilobases of DNA) and repetitive DNA elements are vir tually ubiquitous, other strategies are usually required.
One approach is to attempt to clone the breakpoint of a translocation found to be associated with the disease under study. Such a strategy has been demonstrated by Ray et al.147 who cloned sequences from the Duch enne muscular dystrophy (DMD) locus by using rRNA gene probes to isolate X-chro mosomal material adjacent to ribosomal DNA on an X:21 translocation chromosome. If the disease in question is associated with a deletion, then the most promising and direct way of isolating clones from the disease locus is that described by Kunkel et al. 148 DNA from a Duchenne muscular dystrophy patient with a deletion at Xp21 was sheared and used in a 200-fold excess in a competitive reassociation reaction (PERT) with MboI-digested DNA derived from normal X chromosomes. The rationale of this technique is that only those unique Mbol fragments lacking homologous sequences in the patient's DNA were able to re-hybridise, thus re-creating their MboI 'sticky ends'. These fragments were then cloned into an appropriate vector; seven clones in all were isolated in this fashionl48,149 and some of these were shown not to hybridise to DNA derived from Duchenne muscular dystrophy (DMD) patients with small deletions. 15 0 , 'Long-range restriction mapping'151 of regions of DNA, sometimes several thousand kb in length, has also begun to make a contri bution. Mapping of such large regions has been made possible by the introduction of the new technique of pulsed field gel electro phoresis (PFG). PFG is able to resolve DNA fragments up to many thousands of kb in size and it is this resolving power that provides the means to map very large regions of the chro mosome.152,153 PFG has facilitated the more precise delineation of DMD-associated deletions and translocation breakpoints, 154,155 and confirmed that the DMD gene covers a con siderable area (about 2,000 kb) of the X chromosome.
Further clones from the DMD locus have been isolated by virtue of their sequence con servation between man and mouse156 and one has identified a 16 kb mRNA in total RNA derived from human fetal muscle.156 cDNA clones from the whole of the coding region have now been isolated157 and it will not be long before the entire sequence is known and the molecular basis of even the more subtle mutations causing Duchenne muscular dys trophy, elucidated,
Candidate genes for various other diseases have now also been isolated. These include chronic granulomatous disease, 158 reti noblastoma, 1 � 1 0 8 and cystic fibrosis. 159 Strat egies that were employed in the isolation of these genes have been reviewed by Orkinl6 0 but some discussion is appropriate here , Clearly, strategies will vary according to the presumed chromosome location of the disease gene, the amount of mapping data available, the applicability of different analytical tech niques, the nature of mutations associated with the disease etc. As explained above, cytologically-detectable deletions or trans locations associated with a disease state are of enormous help, both in helping to localise the disease gene, and in facilitating its eventual isolation. When these are not available, link age data derived from segregation analyses using DNA segments or genes as markers, can be used to construct genetic maps of chromo somes. 161 The availability of chromosome specific DNA libraries162 should certainly facilitate the cloning of chromosomally localised disease genes. The advent of pulsed field gel electrophoresis152 and associated new cloning technologiesI46,163--J65 have now enabled the relatively rapid physical mapping of long stretches of DNA between such mark ers. For a long gene, a detailed map of the gene region is required for the accurate demarcation of deletion and translocation breakpoints, which may, as in Duchenne mus cular dystrophy, have caused the disease. Such mapping information will also facilitate the further cloning of DNA fragments from the area of interest. For instance , PFG not only aids map construction but also permits the identification and separation of specific, very large DNA fragments encompassing the disease locus under study. Isolation of these fragments, followed by cloning of the entire region, will hasten the identification of the disease locus itself.
Even for a smaller gene, a physical map of the surrounding chromosomal region can prove immensely valuable for the localisation of putative coding regions through the detec tion of CG-rich 'HTF islands' .1 66 HTF (Hpa II tiny fragment) islands are not only rich in the dinucleotide CG, in contrast to the rest of the genome which is CG-depleted, but also unmethylated. Further, they are thought to be associated with gene sequencesl 6 6-1 6 9 and may therefore potentially act as markers for their precise localisation. This strategy has now proved its worth by potentiating the precise localisation and isolation of, among others, a cystic fibrosis candidate gene.159
The cystic fibrosis study quoted above also illustrates the use that can be made of linkage disequilibrium data in assessing how close a candidate gene sequence may be to the disease gene itself. Linkage disequilibrium, or the non-random association of linked alleles, was found between RFLPs around the cystic fibrosis candidate gene and the disease phe notype for a large sample of cystic fibrosis patients. Interpretation of linkage diseq uilibrium data and its equation with physical distance is a pastime fraught with dangers but it is nevertheless possible to derive an esti mate of the distance from the marker to the disease locus. Since linkage disequilibrium decays rapidly due to recombination, this is only appropriate over very short distances such as the 10 kb between marker and disease locus estimated by Estivill et al. 159 The exis tence of linkage disequilibrium is therefore good a priori evidence that the marker is very close (in molecular genetic terms) to the disease locus.
The location of coding sequences in the region of interest may also be helped by the detection of stretches of DNA in the region which are evolutionarily conserved. Con servation implies function and this in turn implies a coding sequence. Non-repetitive elements from a given human chromosomal region are subcloned and hybridised to DNA from other higher animals to look for sequence conservation.
Obviously, candidate genes must be expressed in appropriate tissues (e.g. the Duchenne muscular dystrophy gene in normal adult muscle) and the tissue pattern of expres sion will provide an important guide to the identity of the gene sequence. Conversely, 'enriched' cDNA, derived from, and specific to the tissue in which the defective gene would exert its pathological effects, may be used to find such genes.
Once we possess a copy of the disease gene itself, how do we use this to determine the nature of any one specific mutation in a given patient? As we have seen, deletions in excess of 100 bp are readily detectable by Southern blotting. However, the majority of mutations causing genetic disease are probably undetec table using this method, and many may be single base-pair substitutions that do not alter restriction enzyme cleavage. One approach is therefore to make a gene library from DNA derived from the patient, isolate the gene by virtue of the homology with the cloned gene and then sequence it to search for the pre sumed base pair difference. Many examples of this type of approach are found in the literature. 1 . 2 Various means are now available for the recognition of changes from a 'prototype' DNA sequence of a given gene which obviate the need for complete sequencing of the mutant gene. One alternative approach to the detection of single base-pair substitutions is that described by Myers.l7O Heteroduplexes between a labelled single stranded beta globin gene probe and fragments derived from denatured digests of genomic DNAs containing different beta-thalasaemia alleles were successfully separated and distinguished by denaturing gradient gel electrophoresis. Modifications of this basic technique have been reportedl7l-173 and should together pro vide the potential to scan gene coding regions for single base-pair mismatches which, once localised, can then be further examined by DNA sequencing.
Another technique which promises greatly to aid mutant gene isolation is that reported by Scharf et at. 174 and reviewed by Mullis et al. 175 The disease gene from the patient's gen ome is specifically amplified by a method known as the 'polymerase chain reaction' . Specific oligonucleotides, homologous to sequences upstream and downstream of the gene, are required to prime the reaction which consists of repetitive cycles of denaturation, primer annealing and polymerase extension , resulting in the amplification of the gene sequence of interest . Genes amplified in this way are present in such high copy number that they may be sequenced directly without the re q uirement of prior cloning.
Mutation in human genes appears to be non-random; some 35 per cent of single base pair substitutions causing human genetic disease occur in the dinucleotide cytosine guanine (CG). 1 76 This is thought to be due to the propensity of cytosine, methylated at the 5 position, to undergo deamination to form thy midine. m. n8 Over 90 per cent of the substitu tions found in CG are cytosine to thymidine or guanine to adenine, consistent with this postulate. 1 76 We suggest, therefore, the use of a directed strategy towards the localisation of specific mutations when the 'prototype' DNA sequence of the gene in question is known. Particular attention should be paid to CG dinucleotides in codons specifying amino acids within important (e.g. protein binding regions or proteolytic cleavage sites) regions of the protein product. Similarly CGA codons are potential hot spots for methylation induced deamination. A C� T transition in this sequence will create a TGA termination codon with potentially deleterious con sequences for the individual concerned. Since mutations at some sites are much more fre quent than others, it follows that the use of directed search strategies, e.g. restriction enzymes which contain CG in their recogni tion sequencel79 or 0ligonucleotides7 specific to predicted sites of mutation, can be expected to optimise the direct detection of gene mutations. A combination therefore of intelligent guesswork, combined with some of the techniques outlined above, should greatly ease the detection and characterisation of human gene mutations.
Eventually, however, proof of the involve ment of a specific cloned gene must come from three sources. The first is the demonstration of a deletion internal to the region encom passed by the candidate cDNA or the detec tion of a single base-pair change within the coding region that is not an RFLP. The second is the absence or alteration of the mRNA corresponding to the cloned candidate gene probe in tissues from patients with the disease, which in healthy individuals, would express that mRNA. The third source of evi dence (discussed in section on reti noblastoma) would be provided by phenotypic correction of the defect by reintroduction of the gene product thought to be lacking in the disease. Wh en these require ments are fulfilled, we are considerably nearer to being able to define a disease in absolute terms and provide a molecular genetic explanation of the morbid pathology of the disease state. 
